首页> 美国卫生研究院文献>OncoTargets and therapy >Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide

【2h】

Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide

机译：趋化因子CCL20涉及骨髓瘤细胞的趋化因子CCL20抵抗Elotuzumab和Lenalidomide

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Few studies have focused on investigating resistance mechanisms in myeloma immunotherapy. This study aimed to explore the relevant factor involved in the resistance of Elotuzumab and lenalidomide.

机译：少数研究侧重于调查骨髓瘤免疫疗法的抗性机制。本研究旨在探讨Elotuzumab和Lenalidomide抗性的相关因素。

著录项

期刊名称 OncoTargets and therapy
作者
Huihan Wang; Hua Shi; Xiaowei He; Aijun Liao;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 7
原文格式 PDF
正文语种
中图分类应用微生物学;肿瘤学;
关键词
CCL20; elotuzumab; lenalidomide; drug resistance; multiple myeloma;

机译：CCL20;Elotuzumab;Lenalidomide;耐药;多发性骨髓瘤;
入库时间 2022-08-21 12:03:46

相似文献

外文文献
中文文献
专利

1. Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma [J] . Iqbal Shumaila Muhammad, Stecklein Kathryn, Sarow Joseph, Clinical lymphoma, myeloma & leukemia . 2019,第1期

机译：Elotuzumab与Lenalidomide和地塞米松组合用于治疗的免疫球蛋白轻链淀粉样蛋白腺苷病，具有多种骨髓瘤
2. Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma [J] . Keren Osman, Ajai Chari, Samir Sunil Parekh, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：Elotuzumab与自体干细胞移植和多个骨髓瘤的活性维持联合研究
3. Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM) [J] . Thomas Sheeba K., Shah Jatin J., Morphey Ashley N., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：多种骨髓瘤（PTS）中Lenalidomide-Elotuzumab作为维护治疗后患者（PTS）的维持治疗的II次级研究结果的更新结果
4. Comparative Proteomic Study of Mechanisms Involved in the Expression of Recombinant Monoclonal Antibody in Non Amplified NSO Myeloma Cell Line [C] . Luis E. Rojas, Kathya R. de la Luz Hernandez, Svieta Victores, General Meeting of European Society of Animal Cell Technology . 2007

机译：对非扩增NSO骨髓瘤细胞系重组单克隆抗体表达的机制的比较蛋白质组学研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression Immune Response and Bone Metabolism [O] . Rodrigo Carlini Fernando, Diego Robles Mazzotti, Hatylas Azevedo, -1

机译：多发性骨髓瘤患者间充质干细胞的转录组分析显示细胞周期进程免疫反应和骨代谢相关基因的下调。
7. Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide [O] . Huihan Wang, Hua Shi, Xiaowei He, 2021

机译：趋化因子CCL20涉及骨髓瘤细胞的趋化因子CCL20抵抗Elotuzumab和Lenalidomide

Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide

摘要

著录项

相似文献

相关主题

期刊订阅